- Report
- March 2024
- 200 Pages
Global
From €3987EUR$4,150USD£3,409GBP
- Clinical Trials
- April 2024
- 75 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- March 2024
- 120 Pages
Global
From €4324EUR$4,500USD£3,697GBP
- Report
- September 2022
- 194 Pages
Global
From €4611EUR$4,799USD£3,942GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Report
- April 2023
- 111 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- April 2022
- 120 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- June 2018
- 55 Pages
Global
From €3839EUR$3,995USD£3,282GBP
- Report
- June 2018
- 162 Pages
Global
From €10564EUR$10,995USD£9,032GBP
- Report
- March 2024
- 80 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Drug Pipelines
- June 2021
- 61 Pages
Global
From €3363EUR$3,500USD£2,875GBP
- Drug Pipelines
- August 2020
- 58 Pages
Global
From €3363EUR$3,500USD£2,875GBP
The Cytomegalovirus Drug market is a subset of the Infectious Diseases Drugs market. It is composed of drugs used to treat cytomegalovirus (CMV) infections, a type of virus that can cause serious health problems in people with weakened immune systems. These drugs are used to reduce the severity of symptoms, prevent complications, and reduce the risk of transmission. Commonly used drugs include ganciclovir, valganciclovir, and foscarnet.
The Cytomegalovirus Drug market is highly competitive, with many companies offering similar products. Some of the major players in the market include Gilead Sciences, Merck & Co., Pfizer, Novartis, and GlaxoSmithKline. Show Less Read more
